Scancell Holdings Share News (SCLP)

TRADING UPDATES: Creo extends contract; Belluscura raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Shares in Scancell climb as strikes exclusive drug evaluation deal

(Alliance News) - Scancell Holdings PLC on Wednesday announced a major international biotechnology company will exclusively evaluate a Scancell investigational anti-glycan monoclonal antibody for development of novel therapeutic products.

Scancell shares jump on new antibody agreement with major biotech firm

(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval from UK's Medicines & Healthcare products Regulatory agency to add a third cohort to the Scope trial. Says the cohort will consist of 43 melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab, under the brand name Yervoy, plus nivolumab, under the name Opdivo. "Exceptional" results from the first 13 patients receiving SCIB1 in the ongoing Scope trial, with an objective response rate of 85%, indicate a high probability of success in this cohort, which is expected to complete in the second quarter of 2024. Meanwhile, recruitment into the iSCIB1+ cohort is expected to be complete by the end of the second quarter as well, with early data expected in the third quarter of 2024.

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares.

IN BRIEF: Scancell raises GBP10.7 million in upsized share sale

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors".

EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

IN BRIEF: Scancell shares up as presents "trailblazing" trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma Research on Thursday. Trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Company reported mid-September that SCIB1 combined with CPIs showed an 82% objective response rate. Scope trial is currently in its second stage. Scancell says on Friday that in Cohort 1 nine responses were achieved earlier than expected, and probability of second-stage success is around 90% based on current data.

EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

IN BRIEF: Scancell says needs more time to publish annual results

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues.